News

Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines AgencyZealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes…

12 months ago
JDRF Walk to Cure DiabetesJDRF Walk to Cure Diabetes

JDRF Walk to Cure Diabetes

Throughout June close to 50 communities will be gathering across Canada to raise funds for type 1 diabetes researchTORONTO, May…

12 months ago
DBV Technologies Announces Plan to Implement ADS Ratio ChangeDBV Technologies Announces Plan to Implement ADS Ratio Change

DBV Technologies Announces Plan to Implement ADS Ratio Change

Châtillon, France, May 31, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN:…

12 months ago
Scryb Announces Closing of Private PlacementScryb Announces Closing of Private Placement

Scryb Announces Closing of Private Placement

Toronto, Ontario--(Newsfile Corp. - May 31, 2024) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb'' or the "Company"), is…

12 months ago
Cosmo Reports Excellent Final Full Year 2023 Financial Results – Increases Operating Profit Guidance for 2024 – Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024Cosmo Reports Excellent Final Full Year 2023 Financial Results – Increases Operating Profit Guidance for 2024 – Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024

Cosmo Reports Excellent Final Full Year 2023 Financial Results – Increases Operating Profit Guidance for 2024 – Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX:…

12 months ago
KindlyMD Announces Pricing of $6.8 Million Initial Public OfferingKindlyMD Announces Pricing of $6.8 Million Initial Public Offering

KindlyMD Announces Pricing of $6.8 Million Initial Public Offering

SALT LAKE CITY, UT / ACCESSWIRE / May 31, 2024 / KindlyMD, Inc. (NASDAQ:KDLY)(NASDAQ:KDLYW) ("KindlyMD" or the "Company"), a patient-first…

12 months ago
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)

mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE…

12 months ago
Cloud DX Reports Results for the First Quarter of 2024Cloud DX Reports Results for the First Quarter of 2024

Cloud DX Reports Results for the First Quarter of 2024

Highlights include 23.7% increase in subscription revenue, 23.7% increase in total revenue, and 70.9% increase in gross profit compared to…

12 months ago
Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase ProgramNovo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program

Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program

BELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--As previously reported, the Board of Directors (the “Board”) of Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the…

12 months ago